Blog
About

4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Selective, tight-binding inhibitors of integrin alpha4beta1 that inhibit allergic airway responses.

      Journal of Medicinal Chemistry

      Vascular Cell Adhesion Molecule-1, Structure-Activity Relationship, Sheep, metabolism, antagonists & inhibitors, Receptors, Lymphocyte Homing, pharmacology, chemistry, chemical synthesis, Oligopeptides, Ligands, Kinetics, Jurkat Cells, Integrins, Integrin alpha4beta1, Humans, physiology, Fibronectins, Epitopes, Drug Design, Cell Line, drug effects, Cell Adhesion, toxicity, Carbachol, prevention & control, immunology, chemically induced, Bronchial Hyperreactivity, Binding Sites, Anti-Allergic Agents, Animals

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Integrin alpha4beta1 mediates leukocyte recruitment, activation, mediator release, and apoptosis inhibition, and it plays a central role in inflammatory pathophysiology. High-affinity, selective inhibitors of alpha4beta1, based on the Leu-Asp-Val (LDV) sequence from the alternatively spliced connecting segment-1 (CS-1) peptide of cellular fibronectin, are described that employ a novel N-terminal peptide "cap" strategy. One inhibitor, BIO-1211, was approximately 10(6)-fold more potent than the starting peptide and exhibited tight-binding properties (koff = 1.4 x 10(-4) s-1, KD = 70 pM), a remarkable finding for a noncovalent, small-molecule inhibitor of a protein receptor. BIO-1211 was also 200-fold selective for the activated form of alpha4beta1, and it stimulated expression of ligand-induced epitopes on the integrin beta1 subunit, a property consistent with occupancy of the receptor's ligand-binding site. Pretreatment of allergic sheep with a 3-mg nebulized dose of BIO-1211 inhibited early and late airway responses following antigen challenge and prevented development of nonspecific airway hyperresponsiveness to carbachol. These results show that highly selective and potent small-molecule antagonists can be identified to integrins with primary specificity for peptide domains other than Arg-Gly-Asp (RGD); they confirm the generality of integrins as small molecule targets; and they validate alpha4beta1 as a therapeutic target for asthma.

          Related collections

          Author and article information

          Journal
          10.1021/jm980673g
          10072689

          Comments

          Comment on this article